Adrenocortical Carcinoma

Common Name(s)

Adrenocortical Carcinoma

Adrenocortical carcinoma is a rare cancer, which comes from the adrenal gland. There are two adrenal glands in the human body, one on the top of each kidney in the abdomen. They are shaped like triangles, and each is about a ½ inch high and 3 inches long.

There are two main types of adrenocortical cancer:

Functioning is the most common type and accounts for about 70 percent of adrenal cancers. These tumors are "functioning" because they make hormones, which may have various effects on the body such as facial hair growth, increased blood pressure, or weight gain.

Non-functioning tumors do not produce hormones.

Adrenocortical carcinoma is a rare cancer, affecting only about 300 to 500 people each year in the United States.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Adrenocortical Carcinoma" for support, advocacy or research.

Logo
National Adrenal Diseases Foundation (NADF)

The National Adrenal Diseases Foundation informs, educates, and supports those with adrenal disease and their families to improve their quality of life.

Last Updated: 13 Oct 2014

View Details
Logo
NET Patient Foundation

The Charity’s objects (“the Objects”) are: 1. to advance the education of the general public (including relevant medical and scientific communities) in all areas relating to NETs. 2. to promote the physical and mental health of those affected by NETs through the provision of support, advice and education to patients, their carers and family members.

Last Updated: 9 Nov 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Adrenocortical Carcinoma" for support, advocacy or research.

Logo
National Adrenal Diseases Foundation (NADF)

The National Adrenal Diseases Foundation informs, educates, and supports those with adrenal disease and their families to improve their quality of life.

http://www.nadf.us

Last Updated: 13 Oct 2014

View Details
Logo
NET Patient Foundation

The Charity’s objects (“the Objects”) are: 1. to advance the education of the general public (including relevant medical and scientific communities) in all areas relating to NETs. 2. to promote the physical and mental health of those affected by NETs through the provision of support, advice and education to patients, their carers and family members.

http://www.netpatientfoundation.org

Last Updated: 9 Nov 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Adrenocortical Carcinoma" returned 172 free, full-text research articles on human participants. First 3 results:

Metastatic adrenocortical carcinoma with a prolonged response to mitotane.
 

Author(s): Sumanta K Pal, Benjamin Gartrell, Carl A Olsson, C A Stein

Journal: Oncology (Williston Park, N.Y.). 2014 Jul;28(7):624-5, 642.

 

Last Updated: 22 Aug 2014

Go To URL
IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma.
 

Author(s): Marine Guillaud-Bataille, Bruno Ragazzon, Aurélien de Reyniès, Claire Chevalier, Isabelle Francillard, Olivia Barreau, Virginie Steunou, Johann Guillemot, Frédérique Tissier, Marthe Rizk-Rabin, Fernande René-Corail, Abir Al Ghuzlan, Guillaume Assié, Xavier Bertagna, Eric Baudin, Yves Le Bouc, Jérôme Bertherat, Eric Clauser

Journal:

 

Insulin-like growth factor 2 (IGF2) overexpression is an important molecular marker of adrenocortical carcinoma (ACC), which is a rare but devastating endocrine cancer. It is not clear whether IGF2 overexpression modifies the biology and growth of this cancer, thus more studies are ...

Last Updated: 5 Aug 2014

Go To URL
Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.
 

Author(s): J S Ross, K Wang, J V Rand, L Gay, M J Presta, C E Sheehan, S M Ali, J A Elvin, E Labrecque, C Hiemstra, J Buell, G A Otto, R Yelensky, D Lipson, D Morosini, J Chmielecki, V A Miller, P J Stephens

Journal: J. Clin. Pathol.. 2014 Nov;67(11):968-73.

 

Adrenocortical carcinoma (ACC) carries a poor prognosis and current systemic cytotoxic therapies result in only modest improvement in overall survival. In this retrospective study, we performed a comprehensive genomic profiling of 29 consecutive ACC samples to identify potential targets ...

Last Updated: 17 Oct 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Adrenocortical Carcinoma" returned 21 free, full-text review articles on human participants. First 3 results:

Giant nonfunctioning adrenocortical carcinoma: a case report and review of the literature.
 

Author(s): Ahmad Almarzouq, Sami Asfar, Sundus Hussain, Adel Al-Hunayan, Saad Aldousari

Journal:

 

Adrenocortical carcinoma is a rare and aggressive malignancy. Patients usually present early with manifestation of abnormal hormone secretion. However, adrenocortical carcinoma can also be nonfunctioning, and such patients present late with a mass effect or distant metastases.

Last Updated: 5 Nov 2014

Go To URL
EJE prize 2014: current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go?
 

Author(s): Cristina L Ronchi, Matthias Kroiss, Silviu Sbiera, Timo Deutschbein, Martin Fassnacht

Journal: Eur. J. Endocrinol.. 2014 Jul;171(1):R1-R11.

 

Adrenocortical carcinoma (ACC) is not only a rare and heterogeneous disease but also one of the most aggressive endocrine tumors. Despite significant advances in the last decade, its pathogenesis is still only incompletely understood and overall therapeutic means are unsatisfactory. ...

Last Updated: 10 Jun 2014

Go To URL
Adrenocortical carcinoma.
 

Author(s): Tobias Else, Alex C Kim, Aaron Sabolch, Victoria M Raymond, Asha Kandathil, Elaine M Caoili, Shruti Jolly, Barbra S Miller, Thomas J Giordano, Gary D Hammer

Journal: Endocr. Rev.. 2014 Apr;35(2):282-326.

 

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy, often with an unfavorable prognosis. Here we summarize the knowledge about diagnosis, epidemiology, pathophysiology, and therapy of ACC. Over recent years, multidisciplinary clinics have formed and the first international ...

Last Updated: 26 Mar 2014

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma
 

Status: Recruiting

Condition Summary: Adrenocortical Carcinoma; Adrenal Cancer; ACC

 

Last Updated: 20 May 2015

Go to URL
Surgery and Heated Chemotherapy for Adrenocortical Carcinoma
 

Status: Recruiting

Condition Summary: Adrenocortical Carcinoma; Peritoneal Carcinomatosis

 

Last Updated: 13 Feb 2015

Go to URL
German Adrenocortical Carcinoma Registry
 

Status: Recruiting

Condition Summary: Adrenocortical Carcinoma

 

Last Updated: 7 Jul 2010

Go to URL